Fluorothiazinon in complex therapy of postoperative infectious-inflammatory complications
- 4 June 2026
- journal article
- Published by Media Sphere Publishing Group in Russian Journal of Anesthesiology and Reanimatology
- No. 3
Abstract
The problem of carbapenem-resistant gram-negative flora in intensive care units (ICUs) is a major challenge for modern critical care. Limitations and toxicity of modern therapeutic options create significant difficulties in management of critically ill patients. A promising alternative is a new domestic drug fluorothiazinon with unique mechanism of action aimed at suppressing virulence of microorganisms rather than their direct eradication. The authors present successful treatment of a patient with postoperative pneumonia, mediastinitis, pleural empyema, and septic shock caused by a strain of Klebsiella pneumoniae with the blaOXA-48-like gene. Therapy with meropenem (in high dose with extended infusion) and fluorothiazinon was followed by positive dynamics with hemodynamic stabilization, regression of organ dysfunction, and improvement of laboratory markers. The authors concluded high clinical efficacy and favorable safety of fluorothiazinon combined with carbapenem for the treatment of infections caused by carbapenem-resistant gram-negative flora. Potential niches for this drug are total or subtotal drug resistance, as well as the need for long-term suppressive therapy for chronic recurrent infections.Keywords
This publication has 19 references indexed in Scilit:
- Polymyxin B Induced Acute Diaphragmatic Paralysis: A Case Report Based on Therapeutic Drug MonitoringPharmacology Research & Perspectives, 2025
- Polymyxin B delivery systems: smart solutions for improved antibacterial activity and reduced toxicityJournal of Drug Targeting, 2025
- Ceftazidime-avibactam resistance in Klebsiella pneumoniae: A growing public health concern across diverse sublineages, 2019–2024Journal of Global Antimicrobial Resistance, 2025
- The Challenge of Treating Infections Caused by Metallo‐β‐Lactamase–Producing Gram-Negative Bacteria: A Narrative ReviewDrugs, 2024
- A pharmacovigilance study of adverse events associated with polymyxins based on the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) databaseExpert Opinion on Drug Safety, 2024
- In Vitro Potency and Spectrum of the Novel Polymyxin MRX-8 Tested against Clinical Isolates of Gram-Negative BacteriaAntimicrobial Agents and Chemotherapy, 2022
- Are there differences between ceftolozane/tazobactam and ceftazidime/avibactam in treating patients with complicated abdominal infections? Evidence from clinical trialsJournal of Chemotherapy, 2022
- Preventative treatment with Fluorothiazinon suppressed Acinetobacter baumannii-associated septicemia in miceThe Journal of Antibiotics, 2022
- Resistance to ceftazidime/avibactam in infections and colonisations by KPC-producing Enterobacterales: a systematic review of observational clinical studiesJournal of Global Antimicrobial Resistance, 2021
- Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in ChinaClinical Microbiology and Infection, 2020